FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1500-1501 November 15, 2001 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Kreitman et al. (July 26 issue)¹ report that an anti-CD22 recombinant immunotoxin (BL22) induced complete remissions in 11 of 16 patients with hairy-cell leukemia that was resistant to cladribine. Although BL22 represents an exciting new approach to the treatment of this disease, the results need to be interpreted cautiously, given the potential life-threatening toxicity of this agent (the hemolytic–uremic syndrome developed in two patients).

When a single course of cladribine was administered by continuous intravenous infusion for seven days to 349 patients with hairy-cell leukemia at Scripps Clinic, 319 patients (91 percent) had an initial complete response, . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Golomb, H. M. (2008). Hairy Cell Leukemia: Treatment Successes in the Past 25 Years. JCO 26: 2607-2609 [Full Text]